A colorectal cancer vaccine developed by researchers at Jefferson, combining Philadelphia University and Thomas Jefferson University, has shown positive results in a Phase I clinical trial, marking a significant early milestone in the effort to harness the immune system against one of the most deadly and increasingly prevalent cancers in the United States.
The trial demonstrated that the approach is safe, with no serious adverse events reported among treated patients. Blood samples collected from participants showed markers of immune activation, an early indication that the colorectal cancer vaccine could successfully activate immune cells to identify and fight colorectal tumors and metastases. Further studies to determine whether the vaccine effectively slows tumor growth are underway, with a Phase II trial planned to begin recruiting patients in the months following the initial results.
Why a colorectal cancer vaccine is urgently needed
Colorectal cancer is currently the second leading cause of cancer deaths in the United States and worldwide, and incidence rates among younger adults are rising. Surgery can cure the disease in many patients when caught early, but the prognosis for those who experience recurrence after surgery is poor. Existing treatment options for recurrent or metastatic colorectal cancer remain limited in their effectiveness for a significant portion of patients.
The development of a colorectal cancer vaccine that could train the immune system to attack cancer cells that spread before or during surgery would represent a fundamentally different therapeutic approach. Rather than treating the disease after recurrence, the vaccine aims to prevent recurrence by equipping the immune system to eliminate residual cancer cells that surgery cannot reach.
According to the Mayo Clinic, colorectal cancer begins as small noncancerous clumps of cells called polyps that form inside the colon, and the disease is most treatable when caught early, underscoring the importance of both early detection and novel preventive treatments.
How the colorectal cancer vaccine works
The scientific foundation of this colorectal cancer vaccine lies in targeting a molecule called GUCY2C, which was identified by Scott Waldman, MD, PhD, of the Sidney Kimmel Cancer Center at Jefferson Health as a tumor antigen specific to colorectal cancer. Tumor antigens are molecules that the immune system can recognize as distinct from normal cells, making them ideal targets for vaccine based immunotherapy.
Cancer cells are derived from normal cells and share nearly all of the same molecular markers, which makes it difficult for the immune system to distinguish cancerous from healthy tissue. GUCY2C offers a specific molecular signpost that allows the immune system to identify and attack colorectal cancer cells without targeting normal tissue.
The vaccine, developed by Adam Snook, PhD, and colleagues, works by linking the GUCY2C molecule with a molecule called PADRE that amplifies the immune response, and loading this combination into an adenovirus vector. This engineered construct is designed to activate killer T cells, the immune cell type responsible for finding and destroying cancer cells, specifically against GUCY2C expressing colon cancer cells.
What the Phase I clinical trial showed
The Phase I trial enrolled 10 patients with stage I or II colon cancer. Each patient received a single dose of the colorectal cancer vaccine and returned for blood draws at 30, 90, and 180 days after immunization. Patients reported some discomfort at the injection site but no serious side effects. Blood sample analysis confirmed activation of killer T cells at the levels the research team had anticipated, providing biological evidence that the vaccine is producing the intended immune response.
“This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type,” said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center at Jefferson Health.
Expanding the potential of the colorectal cancer vaccine
Since initiating the trial, researchers discovered that GUCY2C is expressed not only in colorectal cancer but also in gastric, esophageal, and pancreatic cancers, three of the deadliest cancer types. Together with colorectal cancer, these four cancer types account for approximately 20 percent of all cancer related deaths globally. This finding substantially expands the potential patient population that a GUCY2C targeting vaccine might ultimately benefit.
The planned Phase II trial will evaluate a refined version of the vaccine incorporating lessons from the Phase I study. The goal is to demonstrate improved efficacy and to establish whether the vaccine can benefit a broader group of cancer patients across multiple tumor types.
Clinical research and the path from Phase I to broader impact
The progression of this colorectal cancer vaccine from preclinical mouse studies through Phase I and into Phase II reflects the structured clinical trial process that every cancer therapy must navigate before reaching patients at scale. Each phase builds on the last, generating the safety and efficacy data that regulatory agencies require and that ultimately determines whether a treatment reaches the patients who need it.
FOMAT supports oncology clinical research nationally through its oncology clinical trial capabilities, partnering with sponsors and CROs to conduct Phase I through Phase IV studies in cancer and other serious diseases. Our community based investigator network and diverse patient population provide sponsors with the site infrastructure and recruitment reach needed to advance promising therapies efficiently.
For patients with colorectal cancer or other gastrointestinal cancers who are interested in clinical trial participation, FOMAT’s active studies page provides current information about available research opportunities. For sponsors and CROs evaluating research partners for oncology programs, FOMAT’s Phase I through Phase IV clinical research capabilities offer a proven and scalable solution.